What is the current valuation of the Swine Health Animal Disease Diagnostic Genetics Market?

The market valuation was 2.15 USD Billion in 2024. Read More

What is the projected market size for the Swine Health Animal Disease Diagnostic Genetics Market by 2035?

The market is projected to reach 3.193 USD Billion by 2035. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 3.66%. Read More

Which diagnostic methods are leading in the Swine Health Animal Disease Diagnostic Genetics Market?

PCR Testing and Serological Testing are leading methods, with valuations of 1.2 and 0.8 USD Billion respectively. Read More

What are the primary end users in the Swine Health Animal Disease Diagnostic Genetics Market?

Veterinary Clinics and Research Institutions are primary end users, with valuations of 1.25 and 0.65 USD Billion respectively. Read More

Which diseases are most commonly diagnosed in the Swine Health Animal Disease Diagnostic Genetics Market?

Porcine Reproductive and Respiratory Syndrome is the most common, with a valuation of 1.25 USD Billion. Read More

What types of genetic testing are utilized in the Swine Health Animal Disease Diagnostic Genetics Market?

Genomic Selection and Disease Resistance Testing are key types, valued at 0.75 and 0.65 USD Billion respectively. Read More

Who are the key players in the Swine Health Animal Disease Diagnostic Genetics Market?

Key players include Zoetis, Merck Animal Health, and Boehringer Ingelheim among others. Read More

How does the market for swine health diagnostics compare across different disease types?

The market shows varied valuations, with Porcine Reproductive and Respiratory Syndrome leading at 1.25 USD Billion. Read More

What trends are influencing the growth of the Swine Health Animal Disease Diagnostic Genetics Market?

The growth appears driven by advancements in diagnostic methods and increasing demand from veterinary clinics. Read More

Swine Health Animal Disease Diagnostic Genetics Market

ID: MRFR/MED/41396-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Swine Health Animal Disease Diagnostic Genetics Market Research Report By Diagnostic Method (PCR Testing, Serological Testing, Immunohistochemistry, Microarray Analysis), By End User (Veterinary Clinics, Research Institutions, Pharmaceutical Companies, Livestock Producers), By Disease Type (Porcine Reproductive and Respiratory Syndrome, Swine Influenza, Porcine Epidemic Diarrhea, Classical Swine Fever), By Genetic Testing Type (Genomic Selection, Trait Analysis, Disease Resistance Testing, Parentage Testing) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Swine Health Animal Disease Diagnostic Genetics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Diagnostic Method (USD Billion)
  1. 4.1.1 PCR Testing
  2. 4.1.2 Serological Testing
  3. 4.1.3 Immunohistochemistry
  4. 4.1.4 Microarray Analysis
2. 4.2 Healthcare, BY End User (USD Billion)
  1. 4.2.1 Veterinary Clinics
  2. 4.2.2 Research Institutions
  3. 4.2.3 Pharmaceutical Companies
  4. 4.2.4 Livestock Producers
3. 4.3 Healthcare, BY Disease Type (USD Billion)
  1. 4.3.1 Porcine Reproductive and Respiratory Syndrome
  2. 4.3.2 Swine Influenza
  3. 4.3.3 Porcine Epidemic Diarrhea
  4. 4.3.4 Classical Swine Fever
4. 4.4 Healthcare, BY Genetic Testing Type (USD Billion)
  1. 4.4.1 Genomic Selection
  2. 4.4.2 Trait Analysis
  3. 4.4.3 Disease Resistance Testing
  4. 4.4.4 Parentage Testing
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ceva Santé Animale (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Heska Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 IDEXX Laboratories (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Neogen Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY DISEASE TYPE
6. 6.6 US MARKET ANALYSIS BY GENETIC TESTING TYPE
7. 6.7 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD
8. 6.8 CANADA MARKET ANALYSIS BY END USER
9. 6.9 CANADA MARKET ANALYSIS BY DISEASE TYPE
10. 6.10 CANADA MARKET ANALYSIS BY GENETIC TESTING TYPE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD
13. 6.13 GERMANY MARKET ANALYSIS BY END USER
14. 6.14 GERMANY MARKET ANALYSIS BY DISEASE TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY GENETIC TESTING TYPE
16. 6.16 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD
17. 6.17 UK MARKET ANALYSIS BY END USER
18. 6.18 UK MARKET ANALYSIS BY DISEASE TYPE
19. 6.19 UK MARKET ANALYSIS BY GENETIC TESTING TYPE
20. 6.20 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD
21. 6.21 FRANCE MARKET ANALYSIS BY END USER
22. 6.22 FRANCE MARKET ANALYSIS BY DISEASE TYPE
23. 6.23 FRANCE MARKET ANALYSIS BY GENETIC TESTING TYPE
24. 6.24 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
25. 6.25 RUSSIA MARKET ANALYSIS BY END USER
26. 6.26 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
27. 6.27 RUSSIA MARKET ANALYSIS BY GENETIC TESTING TYPE
28. 6.28 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD
29. 6.29 ITALY MARKET ANALYSIS BY END USER
30. 6.30 ITALY MARKET ANALYSIS BY DISEASE TYPE
31. 6.31 ITALY MARKET ANALYSIS BY GENETIC TESTING TYPE
32. 6.32 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD
33. 6.33 SPAIN MARKET ANALYSIS BY END USER
34. 6.34 SPAIN MARKET ANALYSIS BY DISEASE TYPE
35. 6.35 SPAIN MARKET ANALYSIS BY GENETIC TESTING TYPE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY END USER
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY GENETIC TESTING TYPE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
42. 6.42 CHINA MARKET ANALYSIS BY END USER
43. 6.43 CHINA MARKET ANALYSIS BY DISEASE TYPE
44. 6.44 CHINA MARKET ANALYSIS BY GENETIC TESTING TYPE
45. 6.45 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
46. 6.46 INDIA MARKET ANALYSIS BY END USER
47. 6.47 INDIA MARKET ANALYSIS BY DISEASE TYPE
48. 6.48 INDIA MARKET ANALYSIS BY GENETIC TESTING TYPE
49. 6.49 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD
50. 6.50 JAPAN MARKET ANALYSIS BY END USER
51. 6.51 JAPAN MARKET ANALYSIS BY DISEASE TYPE
52. 6.52 JAPAN MARKET ANALYSIS BY GENETIC TESTING TYPE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY END USER
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY GENETIC TESTING TYPE
57. 6.57 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
58. 6.58 MALAYSIA MARKET ANALYSIS BY END USER
59. 6.59 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
60. 6.60 MALAYSIA MARKET ANALYSIS BY GENETIC TESTING TYPE
61. 6.61 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD
62. 6.62 THAILAND MARKET ANALYSIS BY END USER
63. 6.63 THAILAND MARKET ANALYSIS BY DISEASE TYPE
64. 6.64 THAILAND MARKET ANALYSIS BY GENETIC TESTING TYPE
65. 6.65 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
66. 6.66 INDONESIA MARKET ANALYSIS BY END USER
67. 6.67 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
68. 6.68 INDONESIA MARKET ANALYSIS BY GENETIC TESTING TYPE
69. 6.69 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD
70. 6.70 REST OF APAC MARKET ANALYSIS BY END USER
71. 6.71 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
72. 6.72 REST OF APAC MARKET ANALYSIS BY GENETIC TESTING TYPE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD
75. 6.75 BRAZIL MARKET ANALYSIS BY END USER
76. 6.76 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
77. 6.77 BRAZIL MARKET ANALYSIS BY GENETIC TESTING TYPE
78. 6.78 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD
79. 6.79 MEXICO MARKET ANALYSIS BY END USER
80. 6.80 MEXICO MARKET ANALYSIS BY DISEASE TYPE
81. 6.81 MEXICO MARKET ANALYSIS BY GENETIC TESTING TYPE
82. 6.82 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
83. 6.83 ARGENTINA MARKET ANALYSIS BY END USER
84. 6.84 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
85. 6.85 ARGENTINA MARKET ANALYSIS BY GENETIC TESTING TYPE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENETIC TESTING TYPE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USER
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY GENETIC TESTING TYPE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USER
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY GENETIC TESTING TYPE
99. 6.99 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD
100. 6.100 REST OF MEA MARKET ANALYSIS BY END USER
101. 6.101 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
102. 6.102 REST OF MEA MARKET ANALYSIS BY GENETIC TESTING TYPE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY END USER, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY GENETIC TESTING TYPE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY GENETIC TESTING TYPE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.2.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.3.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.3.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.3.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.4.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.4.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.4.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.5.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.5.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.5.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.6.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.6.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.6.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.7.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.7.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.7.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.8.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.8.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.8.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.9.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.9.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.9.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.10.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.10.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.10.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.11.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.11.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.11.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.12.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.12.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.12.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.13.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.13.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.13.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.14.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.14.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.14.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.15.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.15.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.15.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.16.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.16.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.16.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.17.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.17.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.17.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.18.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.18.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.18.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.19.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.19.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.19.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.20.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.20.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.20.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.21.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.21.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.21.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.22.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.22.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.22.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.23.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.23.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.23.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.24.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.24.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.24.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.25.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.25.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.25.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.26.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.26.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.26.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.27.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.27.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.27.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.28.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.28.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.28.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.29.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.29.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.29.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  2. 7.30.2 BY END USER, 2025-2035 (USD Billion)
  3. 7.30.3 BY DISEASE TYPE, 2025-2035 (USD Billion)
  4. 7.30.4 BY GENETIC TESTING TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

PCR Testing
Serological Testing
Immunohistochemistry
Microarray Analysis

Healthcare By End User (USD Billion, 2025-2035)

Veterinary Clinics
Research Institutions
Pharmaceutical Companies
Livestock Producers

Healthcare By Disease Type (USD Billion, 2025-2035)

Porcine Reproductive and Respiratory Syndrome
Swine Influenza
Porcine Epidemic Diarrhea
Classical Swine Fever

Healthcare By Genetic Testing Type (USD Billion, 2025-2035)

Genomic Selection
Trait Analysis
Disease Resistance Testing
Parentage Testing

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”